Author/Authors :
Ziaie, Shadi Department of Clinical Pharmacy - Faculty of Pharmacy - Shahid Beheshti University of Medical Sciences, Tehran - Department of Nephrology and Kidney Transplantation - Shahid Labbafnejad Medical Center - Shahid Beheshti University of Medical Sciences, Tehran , Koucheck, Mehran Critical Care Medicine Ward - Anesthesiology Department - Imam Hossein (A.S.) Medical and Educational Center - Shahid Beheshti University of Medical Sciences, Tehran , Miri, Mir Mohammad Critical Care Medicine Ward - Anesthesiology Department - Imam Hossein (A.S.) Medical and Educational Center - Shahid Beheshti University of Medical Sciences, Tehran , Salarian, Sara Critical Care Medicine Ward - Anesthesiology Department - Imam Hossein (A.S.) Medical and Educational Center - Shahid Beheshti University of Medical Sciences, Tehran , Shojaei, pouzhia Critical Care Medicine Ward - Anesthesiology Department - Imam Hossein (A.S.) Medical and Educational Center - Shahid Beheshti University of Medical Sciences, Tehran , Haghighi, Mehrdad Department of Infectious Disease - Imam Hossein (A.S.) Medical and Educational Center - Shahid Beheshti University of Medical Sciences, Tehran , Sistanizad, Mohammad Critical Care Medicine Ward - Anesthesiology Department - Imam Hossein (A.S.) Medical and Educational Center - Shahid Beheshti University of Medical Sciences, Tehran
Abstract :
In late December 2019, a cluster of unexplained pneumonia cases has been
reported in Wuhan, China, named coronavirus disease 2019 (COVID -19)
which has been spreading in 204 countries. To date no pharmaceutical products
have been approved for the treatment of this viral pneumonia. Based on rapid
spread of the disease and high disease burden, several agents have been
proposed for treatment of this viral pneumonia, mainly antivirals and
immunomodulator agents and underwent in-vitro, animal and clinical trials.
Some of these agents have been revealed promising preclinical results but, non
of them approved yet. This review aims to summarize the current knowledge
about the mechanism and considerations of widely used investigational agents
that are used in the treatment of COVID-19 as off-label.
Keywords :
COVID-19 , Pneumonia , Antiviral , Immunomodulator , Interferon , IVIG , Tocilizumab , Remdesivir
